close

Agreements

Date: 2013-05-15

Type of information: Clinical research agreement

Compound: clinical development programs

Company: Merck Serono (Germany) Quintiles (USA)

Therapeutic area: Cancer - Oncology - Neurological diseases - Immunological diseases

Type agreement:

clinical research

Action mechanism:

Disease:

Details:

* On May 15, 2013,  Merck Serono, a division of Merck, and Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, have announced a new, five-year clinical development agreement. This strategic collaboration is the first-of-its-kind between a biopharmaceutical company and a biopharmaceutical services provider, creating a comprehensive process that integrates the expertise and experience from both organizations into a single, well-aligned clinical development engine.
In a novel approach to clinical development that is founded on a shared commitment to cost-disciplined science, the collaboration is intended to optimize productivity in the design and execution of studies with a focus on quality, speed and efficiency.
Under this agreement, Merck Serono will shape and lead the strategy of its clinical development programs, with Quintiles directing clinical trial planning and execution. Quintiles also will be a key contributor to Merck Serono’s future clinical trial design activities. In this capacity, Quintiles will focus on delivering superior performance based on optimized clinical trial design and execution strategies, using highly efficient processes and proven technologies.
To fully leverage the expertise of both organizations, leaders from Quintiles will collaborate in strategic decision-making processes affecting the development of the Merck Serono portfolio.
Moving forward, Quintiles will be the sole primary provider of Merck Serono’s outsourced clinical development services for its global clinical programs. The agreement will span the full spectrum of clinical development, from Phase I through to post-marketing approvals.
The agreement reflects a shared commitment between both organizations to delivering optimal performance in clinical development. The objective is to expedite the delivery of new therapeutic options to patients with high medical need across Merck Serono’s core research areas of neurology, oncology, immuno-oncology and immunology.

Financial terms:

Latest news:

Is general: Yes